2016 Garrod Symposium - Overall Evaluation |
OVERALL GARROD SYMPOSIUM EVALUATION
At the conclusion of this program, the participant will be able to:
1. Describe the Canadian Inherited Metabolic Disorders Research Network (CIMDRN) – Results of data from national IEM database, models, and population studies to date.
2. Engage and interface with National patient/ patient support/advocacy groups.
3. Describe natural history models and associations between interventions and outcomes.
4. Describe population based outcomes of different inborn errors of metabolism and available treatments by regions.
5. Describe Rare disease drug development.
6. Describe available evidence for treatment of Rare Biochemical Disorders.
7. Describe value based decision-making policies currently in place and assessment of available health technologies.
8. Describe current and future innovative therapies available such cell based therapies, transplant and medical therapies.
9. Discuss recent enhancements of established therapies.
10. Describe high throughput technologies for personalized management of inborn errors of metabolism and learn about those currently in place in Canada.
11. Enhance patient engagement and improve healthcare awareness of patients’ perception of IEM, treatment and life impact.
1. Describe the Canadian Inherited Metabolic Disorders Research Network (CIMDRN) – Results of data from national IEM database, models, and population studies to date.
2. Engage and interface with National patient/ patient support/advocacy groups.
3. Describe natural history models and associations between interventions and outcomes.
4. Describe population based outcomes of different inborn errors of metabolism and available treatments by regions.
5. Describe Rare disease drug development.
6. Describe available evidence for treatment of Rare Biochemical Disorders.
7. Describe value based decision-making policies currently in place and assessment of available health technologies.
8. Describe current and future innovative therapies available such cell based therapies, transplant and medical therapies.
9. Discuss recent enhancements of established therapies.
10. Describe high throughput technologies for personalized management of inborn errors of metabolism and learn about those currently in place in Canada.
11. Enhance patient engagement and improve healthcare awareness of patients’ perception of IEM, treatment and life impact.